<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210207050284N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-02-26</date_registration>
      <primary_sponsor>Shahre-kord University of Medical Sciences</primary_sponsor>
      <public_title>The effect of intravenous nutrition on weight gain pattern in premature infants</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of two different approaches to intravenous nutrition(TPN) on the pattern of weight gain in preterm infants weighing less than 1500 g admitted to the neonatal intensive care unit(NICU) of Hajar Hospital in Shahrekord</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-04-04</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/54232</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Using Random Number Generator software, a random list of numbers from one to sixty is created.
The first thirty numbers belong to the control group and the next thirty numbers belong to the case group.
According to the order of hospitalization, infants are numbered from one to sixty and are placed in the control or intervention group based on the number.</study_design>
      <phase>3</phase>
      <hc_freetext>Premature newborn.</hc_freetext>
      <i_freetext>Intervention 1: Control group: Dextrose starts with infusion rate of 6 mg / kg / min on the first day of life and its dose is adjusted to provide random blood sugar between 60 and 120 mg / dL. Lipid ( Smoflipid emulsion20%, manufactured by Fresenius Kabi Austria Gmbh, contains soybean oil, medium chain fatty acid, omega 6 rich fish oil, olive oil and fat-soluble vitamins) at a rate of 3 g / kg and amino acid ( aminoven infant solution 10% production of Fresenius Kabi Austria Gmbh containing amino acid) starts at the rate of 5.3 g / kg. Enteral feeding starts at the first opportunity from 10 to 20 ml / kg per day depending on the infant's tolerance and when intral feeding reaches 100 ml / kg per day, intravenous feeding is stopped. Intervention 2: Intervention group: Dextrose begins at an infusion rate of 6 mg / kg / min on the first day of life and is adjusted to randomly adjust blood sugar levels between 60 and 120 mg / dL. Amino acids (10% neonatal amino solution produced by Fresenius Kabi Austria Gmbh containing amino acids) from 1 g / kg per day and lipids (20% Smoflipid emulsion, produced by Fresenius Kabi Austria Gmbh, containing soybean oil, medium chain fatty acid, rich fish oil From omega-6, olive oil and fat-soluble vitamins) start at 0.5 g / kg / day and increase by 1 g / kg both daily to a maximum of 5.3 g / kg / day for amino acids. And reach 3 grams per kilogram per day for lipids. Enteral feeding starts at the first opportunity from 10 to 20 ml / kg per day depending on the infant's tolerance and when intral feeding reaches 100 ml / kg per day, intravenous feeding is stopped.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Roya Choopani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Kashani Blvd., Headquarters of Shahrekord University of Medical Sciences</address>
        <city>Shahrekord</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8815713471</zip>
        <telephone>+98 38 3333 0061</telephone>
        <email>dr.choopani@yahoo.com</email>
        <affiliation>Shahre-kord University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Roya Choopani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Kashani Blvd., Headquarters of Shahrekord University of Medical Sciences</address>
        <city>Shahrekord</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8815713471</zip>
        <telephone>+98 38 3333 0061</telephone>
        <email>dr.choopani@yahoo.com</email>
        <affiliation>Shahre-kord University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Premature neonate less than 1500 g</inclusion_criteria>
      <agemin>1 day</agemin>
      <agemax>3 days</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Congenital anomaly
Syndromic features
Age over three days
Severe illness
Gestational age more than 37 weeks
Weight more than 1500 grams</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>P07.30</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Preterm newborn, unspecified weeks of gestation</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control group: Dextrose starts with infusion rate of 6 mg / kg / min on the first day of life and its dose is adjusted to provide random blood sugar between 60 and 120 mg / dL. Lipid ( Smoflipid emulsion20%, manufactured by Fresenius Kabi Austria Gmbh, contains soybean oil, medium chain fatty acid, omega 6 rich fish oil, olive oil and fat-soluble vitamins) at a rate of 3 g / kg and amino acid ( aminoven infant solution 10% production of Fresenius Kabi Austria Gmbh containing amino acid) starts at the rate of 5.3 g / kg. Enteral feeding starts at the first opportunity from 10 to 20 ml / kg per day depending on the infant's tolerance and when intral feeding reaches 100 ml / kg per day, intravenous feeding is stopped.</i_keyword>
      <i_keyword>Intervention group: Dextrose begins at an infusion rate of 6 mg / kg / min on the first day of life and is adjusted to randomly adjust blood sugar levels between 60 and 120 mg / dL. Amino acids (10% neonatal amino solution produced by Fresenius Kabi Austria Gmbh containing amino acids) from 1 g / kg per day and lipids (20% Smoflipid emulsion, produced by Fresenius Kabi Austria Gmbh, containing soybean oil, medium chain fatty acid, rich fish oil From omega-6, olive oil and fat-soluble vitamins) start at 0.5 g / kg / day and increase by 1 g / kg both daily to a maximum of 5.3 g / kg / day for amino acids. And reach 3 grams per kilogram per day for lipids. Enteral feeding starts at the first opportunity from 10 to 20 ml / kg per day depending on the infant's tolerance and when intral feeding reaches 100 ml / kg per day, intravenous feeding is stopped.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Weight. Timepoint: Daily and 40th weeks of gestational age. Method of measurement: Scales.</prim_outcome>
      <prim_outcome>Height. Timepoint: Weekly and 40th weeks of gestational age. Method of measurement: Meters.</prim_outcome>
      <prim_outcome>Head circumference. Timepoint: Weekly and 40th weeks of gestational age. Method of measurement: Meters.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahre-kord University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-06-28</approval_date>
        <contact_name>Ethics Committee of Shahrekord University of Medical Sciences</contact_name>
        <contact_address>Kashani Street,Vice Chancellor for Research, Shahrekord University of Medical Sciences Shahrekord Chahar-Mahal-va-Bakhtiari Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
